Key statistics
On Monday, Evotec SE (EVT:FRA) closed at 9.19, 79.57% above the 52 week low of 5.12 set on Aug 07, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 8.50 |
---|---|
High | 9.29 |
Low | 8.50 |
Bid | -- |
Offer | -- |
Previous close | 9.19 |
Average volume | 361.39k |
---|---|
Shares outstanding | 177.55m |
Free float | 158.04m |
P/E (TTM) | -- |
Market cap | 1.51bn EUR |
EPS (TTM) | -0.9668 EUR |
Data delayed at least 15 minutes, as of Nov 25 2024 18:08 GMT.
More ▼
- EQS-Adhoc: Comment on withdrawn non-binding offer
- EQS-Adhoc: Comment on media report
- EQS-PVR: Evotec SE: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
- EQS-News: Evotec SE reports 9M 2024 results: Strategic Progress and Successful Expansion Amid Challenging Market Conditions
- EQS-News: Evotec Announces Sale of API Manufacturing Facility to Monacum Partners
- EQS-News: Evotec SE to announce results for the first nine months 2024 on 06 November 2024
- EQS-News: Evotec and Bristol Myers Squibb expand proteomics partnership
- EQS-DD: Evotec SE: Laetitia Rouxel, Restricted shares granted as Short-Term Variable Incentive (Bonus) for 2023 pursuant Evotec’s remuneration system
- EQS-News: Evotec and Novo Nordisk enter into technology development partnership to support next-generation cell therapies
- EQS-News: Just – Evotec Biologics opens cutting-edge biologics facility - J.POD® Toulouse, France (EU)
More ▼